Tricuspid RegurgitAtion rIsk modeL Study (TRAIL Study)

NCT06926959 · tracked via the Priya Life Science China tracker

Sponsor

Sun Yat-sen University

Phase

Observational

Started

2016-06-15

Last updated

2025-04-15

Condition(s) studied

Tricuspid Regurgitation

Study summary

This study is a multicenter cohort study including patients diagnosed with tricuspid regurgitation during hospitalization. The primary outcome of the study is all-cause death, and the secondary outcome is cardiovascular events. The prognostic risk factors of patients with tricuspid regurgitation are evaluated, and the prognostic models are constructed through the follow-up observation.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Aged over 18 yrs. * Patients diagnosed with tricuspid regurgitation during hospitalization. Exclusion Criteria: * Patients unable to provide informed consent.

Primary outcome measure(s)

all-cause mortality — Through study completion, an average of 5 years
Death due to any cause after enrollment

Trial sites (7)

Facility	City	Region	Status
The First Affiliated Hospital of Sun Yat-sen Univerity	Guangzhou	Guangdong	Recruiting
Third Affiliated Hospital, Sun Yat-Sun University,	Guangzhou	Guangdong	Active Not Recruiting
Jieyang People's Hospital	Jieyang	Guangdong	Active Not Recruiting
Second Affiliated Hospital of Shantou University Medical College	Shantou	Guangdong	Active Not Recruiting
Eighth Affiliated Hospital, Sun Yat-Sen University	Shenzhen	Guangdong	Active Not Recruiting
Affiliated Hospital of Guangdong Medical University	Zhanjiang	Guangdong	Active Not Recruiting
Zhongshan People's Hospital	Zhongshan	Guangdong	Active Not Recruiting

More Sun Yat-sen University trials in China

A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Starting soon

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC Recruiting

Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases Recruiting

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study Recruiting

Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Active, not recruiting

Other trials for the same condition

Concomitant Tricuspid Repair in Patients With Left Heart Surgery Starting soon

SQ-Kyrin-T First-in-man Feasibility Study Active, not recruiting

Active Post-Market Surveillance of Innovative Devices for Valvular Heart Disease Starting soon

Pacemaker-related Tricuspid Regurgitation Progression and Long-term Outcomes Recruiting

Band Versus Ring for Tricuspid Regurgitation Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06926959 on ClinicalTrials.gov ↗ ← All trials in China